Sponsored by
Lots of news coming from GBM CAR-T trials this month. This one from Mass General Cancer Center reported on the first 3 patients enrolled in the trial. All 3 experienced significant reductions in tumor size within a few days of a single infusion of the trial treatment (CAR-T cells + T-cell engaging antibody molecules). However, all 3 eventually had progression. The next step may be testing multiple infusions or testing the treatment together with chemotherapy to get more durable response.